Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in July 2018 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

On 26 November 2010, orphan designation (EU/3/10/814) was granted by the European Commission to Baxter Innovations GmbH, Austria, for recombinant human von Willebrand factor for the treatment of von Willebrand disease.

In May 2015, Baxter Innovations GmbH changed name to Baxalta Innovations GmbH.

Key facts

Active substance
Recombinant human von Willebrand factor
Disease / condition
Treatment of von Willebrand disease
Date of first decision
EU designation number

Review of designation

Sponsor's contact details

Baxalta Innovations GmbH
Industriestrasse 67
A – 1221 Vienna
Telephone: +43 1 20 100 247 2542
Telefax: +43 1 20 100 547 5990

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating
1 rating